ATE452185T1 - Dimethylarginin-dimethylaminohydrolasen - Google Patents

Dimethylarginin-dimethylaminohydrolasen

Info

Publication number
ATE452185T1
ATE452185T1 AT00901731T AT00901731T ATE452185T1 AT E452185 T1 ATE452185 T1 AT E452185T1 AT 00901731 T AT00901731 T AT 00901731T AT 00901731 T AT00901731 T AT 00901731T AT E452185 T1 ATE452185 T1 AT E452185T1
Authority
AT
Austria
Prior art keywords
dimethylarginine
dimethylaminohydrolases
ddahs
activators
genes
Prior art date
Application number
AT00901731T
Other languages
English (en)
Inventor
Patrick John Thompson Vallance
James Mitchell Leiper
Guy St John Whitley
Ian George Charles
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901705.5A external-priority patent/GB9901705D0/en
Priority claimed from GBGB9913066.8A external-priority patent/GB9913066D0/en
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE452185T1 publication Critical patent/ATE452185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
AT00901731T 1999-01-26 2000-01-26 Dimethylarginin-dimethylaminohydrolasen ATE452185T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9901705.5A GB9901705D0 (en) 1999-01-26 1999-01-26 Screen method
GBGB9913066.8A GB9913066D0 (en) 1999-06-04 1999-06-04 Screen method
PCT/GB2000/000226 WO2000044888A2 (en) 1999-01-26 2000-01-26 Dimethylarginine dimethylaminohydrolases

Publications (1)

Publication Number Publication Date
ATE452185T1 true ATE452185T1 (de) 2010-01-15

Family

ID=26315038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901731T ATE452185T1 (de) 1999-01-26 2000-01-26 Dimethylarginin-dimethylaminohydrolasen

Country Status (8)

Country Link
US (1) US20050153315A1 (de)
EP (1) EP1144605B1 (de)
JP (1) JP2002535001A (de)
AT (1) ATE452185T1 (de)
AU (1) AU2303800A (de)
DE (1) DE60043533D1 (de)
ES (1) ES2336416T3 (de)
WO (1) WO2000044888A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020449D0 (en) * 2000-08-18 2000-10-11 Univ London Crystal structure
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US20040214264A1 (en) * 2002-04-19 2004-10-28 Veli-Pekka Valkonen Nucleic acid molecule encoding a variant DDAH 1 protein and uses thereof
GB0211295D0 (en) * 2002-05-16 2002-06-26 Univ London Treatment of pain
GB0211297D0 (en) * 2002-05-16 2002-06-26 Univ London Pain treatment
EP1527102A4 (de) * 2002-05-31 2006-06-21 Unither Pharma Inc Proteine und verfahren, die sich für das abschätzen des risikos von herz-kreislauf-krankheiten eignen
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
CA2615617A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
JP2010518123A (ja) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
CA2753121A1 (en) * 2009-02-20 2010-08-26 Cdg Therapeutics, Inc. Compositions and methods to prevent and/or treat cancer with pa-card
US8486179B2 (en) * 2009-10-29 2013-07-16 Georgia Tech Research Corporation Method for producing carbon molecular sieve membranes in controlled atmospheres
WO2012158518A1 (en) * 2011-05-13 2012-11-22 The Penn State Research Foundation Treatment of renal injury
EP3661543A4 (de) * 2017-07-31 2021-09-22 The Trustees of Indiana University Modifizierte ddah-polypeptide mit einer pharmakokinetisch verstärkenden einheit, verbesserte pharmakologie und ihre verwendungen
JP2022548026A (ja) 2019-09-13 2022-11-16 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 血液中のａｄｍａを調節するデバイスおよび方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0965876A (ja) * 1995-08-31 1997-03-11 Green Cross Corp:The 動物細胞の振盪培養方法および培養容器
DE69736673T2 (de) * 1996-08-20 2007-09-13 Novartis Ag Rifamycin biosynthese genkluster
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
DE19820190A1 (de) * 1998-04-28 1999-11-04 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor
CA2350388A1 (en) * 1998-11-12 2000-05-18 Incyte Pharmaceuticals, Inc. Human hydrolase proteins

Also Published As

Publication number Publication date
DE60043533D1 (de) 2010-01-28
EP1144605B1 (de) 2009-12-16
ES2336416T3 (es) 2010-04-13
WO2000044888A3 (en) 2001-12-13
JP2002535001A (ja) 2002-10-22
US20050153315A1 (en) 2005-07-14
EP1144605A2 (de) 2001-10-17
EP1144605A3 (de) 2002-03-27
WO2000044888A2 (en) 2000-08-03
AU2303800A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
ATE452185T1 (de) Dimethylarginin-dimethylaminohydrolasen
NO20051107L (no) Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet
DE69936720D1 (de) Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
BR9916785A (pt) Tratamento de asma com inibidores mek
NO20052928L (no) Nye kjemiske forbindelser
NO20051788L (no) Hydantoinderivater og deres anvendelse som TACE-inhibitorer
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
NO20035086D0 (no) Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
NO20033742D0 (no) Omega-aminoalkylamider av R-2-arylpropionsyrer som inhibitorer av polymofonukle¶re og mononukle¶re cellers kjemotakse
NO20083032L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
EP1191941A4 (de) Methode der prophylaxe und/oder behandlung von erkrankungen
MY117526A (en) N-(3-benzofuranyl)urea-derivatives
NO971444L (no) Inhibitor av stamcelle-proliferasjon og anvendelser derav
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
DE50308707D1 (de) Abbau und modifizierung von silicaten und siliconen durch silicase und verwendung des reversiblen enzyms
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
PL375795A1 (en) Agents containing carboxylic acid and the use of the same in plant cultivation
NO20020130D0 (no) Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrering eller kjemotaksis
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
NO20054670D0 (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
JOP20240149A1 (ar) مثبطات bcl-2 (الخلية ب لمفومة 2)
SG155901A1 (en) Enzyme inhibitors and uses thereof
EP1514935A4 (de) DIE PFLANZENBLÜTE FÖRDERNDES GEN Ehd1 UND SEINE NUTZUNG

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties